cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2013-6-29-33cardiovascular-97Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMКОМБИНАЦИЯ ИНГИБИТОРА АНГИОТЕНЗИН-ПРЕВРАЩАЮЩЕГО ФЕРМЕНТА И БЛОКАТОРА КАЛЬЦИЕВЫХ КАНАЛОВ У ПАЦИЕНТОВ С СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ И СОХРАНЕННОЙ СИСТОЛИЧЕСКОЙ ФУНКЦИЕЙ НА ФОНЕ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ — ЕСТЬ ЛИ МЕСТО ОСОЗНАННОМУ ВЫБОРУ?COMBINATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND CALCIUM CHANNEL BLOCKERS IN HYPERTENSIVE PATIENTS WITH HEART FAILURE AND PRESERVED SYSTOLIC FUNCTION: IS THERE A PLACE FOR AN INFORMED CHOICE?ЖировИ. В.ZhirovI. V.

вед.н.с. отдела заболеваний миокарда и сердечной недостаточности

Тел.: (495) 414–67–88 

izhirov@mail.ruНиколаеваО. А.NikolaevaO. A.

аспирант отдела

ТерещенкоС. Н.TereshchenkoS. N.

руководитель отдела

НИИ кардиологии им. А.Л. Мясникова ФБГУ “РКНПК” Минздрава России, МоскваA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Moscow2013201220131262933Copyright © Жиров И.В., Николаева О.А., Терещенко С.Н., 20132013Жиров И.В., Николаева О.А., Терещенко С.Н.Zhirov I.V., Nikolaeva O.A., Tereshchenko S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/97

Представлены данные о перспективе применения комбинации антагониста кальция и ингибитора ангиотензин-превращающего фермента в лечении пациентов с хронической сердечной недостаточностью и сохраненной фракцией выброса левого желудочка на фоне артериальной гипертонии. Показана целесообразность применения лизиноприла в такой комбинации. 

The authors present the data on the potential of the combination of angiotensin-converting enzyme inhibitors and calcium channel antagonists in the treatment of hypertensive patients with chronic heart failure and preserved left ventricular ejection fraction. The informed choice of lisinopril, as a component of such a combination, is justified. 

ингибитор ангиотензин-превращающего ферментаамлодипинлизиноприлхроническая сердечная недостаточность с сохраненной систолической функцией левого желудочкаangiotensin-converting enzyme inhibitorlisinoprilamlodipinechronic heart failure with preserved left ventricular systolic functionReferencesTereschenko S, Dzhaiani N, Zhirov I, Uskach T. Chronic heart failure. The diagnosis and treatment. M.: Anakharsis, 2006; 80 p. Russian (Терещенко С.Н., Джаиани Н.А., Жиров И.В., Ускач Т.М. Хроническая сердечная недостаточность. Вопросы диагностики и лечения. М.: “Анахарсис” 2006; 80 с).Tereschenko S, Dzhaiani N, Zhirov I, Uskach T. Chronic heart failure. The diagnosis and treatment. M.: Anakharsis, 2006; 80 p. Russian (Терещенко С.Н., Джаиани Н.А., Жиров И.В., Ускач Т.М. Хроническая сердечная недостаточность. Вопросы диагностики и лечения. М.: “Анахарсис” 2006; 80 с).Sanderson JE. Heart failure with a normal ejection fraction. Heart 2007; 93:155–8.Sanderson JE. Heart failure with a normal ejection fraction. Heart 2007; 93:155–8.Mareev V, et al. EPOCHE-CHF. J Heart Failure 2011; 12 (5): 254–62. Russian (Мареев В.Ю. и др. ЭПОХА-ХСН. Сердечная Недостаточность 2011; 12 (5): 254–62).Mareev V, et al. EPOCHE-CHF. J Heart Failure 2011; 12 (5): 254–62. Russian (Мареев В.Ю. и др. ЭПОХА-ХСН. Сердечная Недостаточность 2011; 12 (5): 254–62).ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart J 2012:33; 1787–847.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart J 2012:33; 1787–847.Fernandez JH, Hayashi MAF, Camargo ACM, Neshich G. Strucural basis of the lisinopril-binding specificity in N- and C-domains of human somatic ACE. Biochem Biophys Res Communic 2003; 308: 219–26.Fernandez JH, Hayashi MAF, Camargo ACM, Neshich G. Strucural basis of the lisinopril-binding specificity in N- and C-domains of human somatic ACE. Biochem Biophys Res Communic 2003; 308: 219–26.Dickstein K, Aarsland T, Woie L, et al. Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure. Am Heart J 1986; 112 (1): 121–9.Dickstein K, Aarsland T, Woie L, et al. Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure. Am Heart J 1986; 112 (1): 121–9.Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100 (23): 2312–8.Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100 (23): 2312–8.Packer M, Lee WH, Medina N, et al. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. JACC 1987; 10: 1303–11.Packer M, Lee WH, Medina N, et al. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. JACC 1987; 10: 1303–11.Witchitz S, Haiat R, Tarrade T, et al. Accidents cardio-vasculaires au cours des traitements par le verapamil: a propos de 6 observations. Nouv Press Med 1975;4:337–8.Witchitz S, Haiat R, Tarrade T, et al. Accidents cardio-vasculaires au cours des traitements par le verapamil: a propos de 6 observations. Nouv Press Med 1975;4:337–8.Elkayam U, Weber L, McKay C, et al. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol 1985;56:560–6.Elkayam U, Weber L, McKay C, et al. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol 1985;56:560–6.Packer M, Lee WH, Medina N, Yushak M. Comparative negative inotropic effects of nifedipine and diltiazem in patients with severe left ventricular dysfunction. Circulation 1985;72: Suppl III: III-275.Packer M, Lee WH, Medina N, Yushak M. Comparative negative inotropic effects of nifedipine and diltiazem in patients with severe left ventricular dysfunction. Circulation 1985;72: Suppl III: III-275.Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954–61.Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954–61.Goldstein RE, Boccuzzi SJ, Cruess D, Adverse Experience Committee, Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52–60.Goldstein RE, Boccuzzi SJ, Cruess D, Adverse Experience Committee, Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52–60.The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385–92.The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385–92.Ferlinz J, Gallo CT. Responses of patients in heart failure to long-term oral verapamil administration. Circulation 1984;70: Suppl II: II-305.Ferlinz J, Gallo CT. Responses of patients in heart failure to long-term oral verapamil administration. Circulation 1984;70: Suppl II: II-305.Kloner R., Sowers J., DiBona G. et al. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996;77:713–22.Kloner R., Sowers J., DiBona G. et al. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996;77:713–22.Packer M, O`Connor C, Ghali J, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335;1107–14.Packer M, O`Connor C, Ghali J, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335;1107–14.Lewington S, Clarke R, Qizilbash N, et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903–13.Lewington S, Clarke R, Qizilbash N, et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903–13.Miura K, Daviglus ML, Dyer AR, et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161 (12): 1501–8.Miura K, Daviglus ML, Dyer AR, et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161 (12): 1501–8.Protassov K, Fedorishina O, Dzisinskiy A, et al. The nephroprotective effect of fixed combination of lisinopril and amlodipine in patients with diabetes mellitus and arterial hypertension. Sistemnye gipertensii 2011; 4: 10–5. Russian (Протасов К. В., Федоришина О. В., Дзизинский А. А. и др. Нефропротективный эффект фиксированной комбинации лизиноприла и амлодипина у больных сахарным диабетом и артериальной гипертензией. Системные гипертензии 2011; 1: 10–5).Protassov K, Fedorishina O, Dzisinskiy A, et al. The nephroprotective effect of fixed combination of lisinopril and amlodipine in patients with diabetes mellitus and arterial hypertension. Sistemnye gipertensii 2011; 4: 10–5. Russian (Протасов К. В., Федоришина О. В., Дзизинский А. А. и др. Нефропротективный эффект фиксированной комбинации лизиноприла и амлодипина у больных сахарным диабетом и артериальной гипертензией. Системные гипертензии 2011; 1: 10–5).Chazova I, Ratova L, Nedogoda S, et al. The use of fixed combination of lisinopril and amlodipine in patients with arterial hypertension. Sistemnye gipertensii 2012; 1: 46–9. Russian (Чазова И.Е., Ратова Л.Г., Недогода С.В. и др. Применение фиксированной комбинации лизиноприла с амлодипином у пациентов с артериальной гипертензией. Системные гипертензии 2012; 1: 46–9).Chazova I, Ratova L, Nedogoda S, et al. The use of fixed combination of lisinopril and amlodipine in patients with arterial hypertension. Sistemnye gipertensii 2012; 1: 46–9. Russian (Чазова И.Е., Ратова Л.Г., Недогода С.В. и др. Применение фиксированной комбинации лизиноприла с амлодипином у пациентов с артериальной гипертензией. Системные гипертензии 2012; 1: 46–9).Sunagawa K, Lowell Maughan W, Burkhoff D, Sagawa K. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol 1983;245: H773–80.Sunagawa K, Lowell Maughan W, Burkhoff D, Sagawa K. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol 1983;245: H773–80.Arutyunov G. New widely discussed clinically significant aspects of beta-blockers influence. Sistemnye gipertensii 2013; 1: 80–7. Russian (Арутюнов Г.П. Новые широко обсуждаемые клинически значимые аспекты влияния бета-адреноблокаторов. Системные гипертензии 2013; 1: 80–7).Arutyunov G. New widely discussed clinically significant aspects of beta-blockers influence. Sistemnye gipertensii 2013; 1: 80–7. Russian (Арутюнов Г.П. Новые широко обсуждаемые клинически значимые аспекты влияния бета-адреноблокаторов. Системные гипертензии 2013; 1: 80–7).

The authors declare that there are no conflicts of interest present.